vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and ThredUp Inc. (TDUP). Click either name above to swap in a different company.

ThredUp Inc. is the larger business by last-quarter revenue ($81.7M vs $74.7M, roughly 1.1× Health Catalyst, Inc.). ThredUp Inc. runs the higher net margin — -7.9% vs -121.9%, a 114.0% gap on every dollar of revenue. On growth, ThredUp Inc. posted the faster year-over-year revenue change (14.6% vs -6.2%). Over the past eight quarters, ThredUp Inc.'s revenue compounded faster (10.6% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ThredUp Inc. is an American company that operates an online resale platform specializing in the sale of second-hand clothing, footwear, and accessories. Founded in 2009 and headquartered in Oakland, California, it has established itself as one of the leading resale fashion marketplaces.

HCAT vs TDUP — Head-to-Head

Bigger by revenue
TDUP
TDUP
1.1× larger
TDUP
$81.7M
$74.7M
HCAT
Growing faster (revenue YoY)
TDUP
TDUP
+20.7% gap
TDUP
14.6%
-6.2%
HCAT
Higher net margin
TDUP
TDUP
114.0% more per $
TDUP
-7.9%
-121.9%
HCAT
Faster 2-yr revenue CAGR
TDUP
TDUP
Annualised
TDUP
10.6%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HCAT
HCAT
TDUP
TDUP
Revenue
$74.7M
$81.7M
Net Profit
$-91.0M
$-6.5M
Gross Margin
79.2%
Operating Margin
-115.3%
12.8%
Net Margin
-121.9%
-7.9%
Revenue YoY
-6.2%
14.6%
Net Profit YoY
-340.3%
-24.1%
EPS (diluted)
$-1.29
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
TDUP
TDUP
Q1 26
$81.7M
Q4 25
$74.7M
$79.7M
Q3 25
$76.3M
$82.2M
Q2 25
$80.7M
$77.7M
Q1 25
$79.4M
$71.3M
Q4 24
$79.6M
$67.3M
Q3 24
$76.4M
$61.5M
Q2 24
$75.9M
$66.7M
Net Profit
HCAT
HCAT
TDUP
TDUP
Q1 26
$-6.5M
Q4 25
$-91.0M
$-5.6M
Q3 25
$-22.2M
$-4.2M
Q2 25
$-41.0M
$-5.2M
Q1 25
$-23.7M
$-5.2M
Q4 24
$-20.7M
$-21.7M
Q3 24
$-14.7M
$-24.8M
Q2 24
$-13.5M
$-14.0M
Gross Margin
HCAT
HCAT
TDUP
TDUP
Q1 26
79.2%
Q4 25
79.6%
Q3 25
52.6%
79.4%
Q2 25
79.5%
Q1 25
79.1%
Q4 24
80.4%
Q3 24
47.5%
79.3%
Q2 24
78.8%
Operating Margin
HCAT
HCAT
TDUP
TDUP
Q1 26
12.8%
Q4 25
-115.3%
-8.4%
Q3 25
-22.9%
-5.3%
Q2 25
-46.0%
-6.8%
Q1 25
-25.4%
-7.6%
Q4 24
-22.0%
-12.1%
Q3 24
-17.9%
-17.0%
Q2 24
-20.8%
-14.4%
Net Margin
HCAT
HCAT
TDUP
TDUP
Q1 26
-7.9%
Q4 25
-121.9%
-7.0%
Q3 25
-29.1%
-5.2%
Q2 25
-50.8%
-6.7%
Q1 25
-29.9%
-7.3%
Q4 24
-26.0%
-32.3%
Q3 24
-19.3%
-40.3%
Q2 24
-17.8%
-20.9%
EPS (diluted)
HCAT
HCAT
TDUP
TDUP
Q1 26
$-0.05
Q4 25
$-1.29
$-0.06
Q3 25
$-0.32
$-0.03
Q2 25
$-0.59
$-0.04
Q1 25
$-0.35
$-0.04
Q4 24
$-0.33
$-0.19
Q3 24
$-0.24
$-0.22
Q2 24
$-0.23
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
TDUP
TDUP
Cash + ST InvestmentsLiquidity on hand
$95.7M
$39.0M
Total DebtLower is stronger
$153.3M
$17.7M
Stockholders' EquityBook value
$245.8M
$59.4M
Total Assets
$502.6M
$172.4M
Debt / EquityLower = less leverage
0.62×
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
TDUP
TDUP
Q1 26
$39.0M
Q4 25
$95.7M
$38.6M
Q3 25
$91.5M
$46.2M
Q2 25
$97.3M
$41.0M
Q1 25
$342.0M
$41.1M
Q4 24
$392.0M
$31.9M
Q3 24
$387.3M
$43.7M
Q2 24
$308.3M
$44.8M
Total Debt
HCAT
HCAT
TDUP
TDUP
Q1 26
$17.7M
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Stockholders' Equity
HCAT
HCAT
TDUP
TDUP
Q1 26
$59.4M
Q4 25
$245.8M
$59.2M
Q3 25
$331.9M
$59.1M
Q2 25
$347.5M
$60.2M
Q1 25
$376.8M
$56.1M
Q4 24
$365.2M
$56.3M
Q3 24
$355.0M
$69.3M
Q2 24
$357.0M
$86.5M
Total Assets
HCAT
HCAT
TDUP
TDUP
Q1 26
$172.4M
Q4 25
$502.6M
$167.2M
Q3 25
$587.1M
$172.5M
Q2 25
$616.2M
$173.6M
Q1 25
$891.5M
$172.5M
Q4 24
$858.9M
$171.2M
Q3 24
$813.0M
$214.9M
Q2 24
$691.7M
$231.2M
Debt / Equity
HCAT
HCAT
TDUP
TDUP
Q1 26
0.30×
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
TDUP
TDUP
Operating Cash FlowLast quarter
$9.9M
$4.8M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
TDUP
TDUP
Q1 26
$4.8M
Q4 25
$9.9M
$-1.5M
Q3 25
$-464.0K
$6.0M
Q2 25
$-9.0M
$344.0K
Q1 25
$280.0K
$5.7M
Q4 24
$-3.5M
$663.0K
Q3 24
$6.2M
$3.3M
Q2 24
$1.6M
$-5.0M
Free Cash Flow
HCAT
HCAT
TDUP
TDUP
Q1 26
Q4 25
$9.6M
$-3.2M
Q3 25
$-719.0K
$2.4M
Q2 25
$-9.2M
$-2.9M
Q1 25
$-390.0K
$3.9M
Q4 24
$-3.9M
$-1.8M
Q3 24
$5.5M
$1.2M
Q2 24
$1.3M
$-5.8M
FCF Margin
HCAT
HCAT
TDUP
TDUP
Q1 26
Q4 25
12.9%
-4.0%
Q3 25
-0.9%
2.9%
Q2 25
-11.4%
-3.8%
Q1 25
-0.5%
5.5%
Q4 24
-4.9%
-2.7%
Q3 24
7.2%
2.0%
Q2 24
1.7%
-8.7%
Capex Intensity
HCAT
HCAT
TDUP
TDUP
Q1 26
Q4 25
0.4%
2.2%
Q3 25
0.3%
4.4%
Q2 25
0.3%
4.2%
Q1 25
0.8%
2.5%
Q4 24
0.5%
3.7%
Q3 24
0.9%
3.5%
Q2 24
0.4%
1.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

TDUP
TDUP

Segment breakdown not available.

Related Comparisons